Teva Seeks To Draw A Line Under Opioids Litigation With Final US Settlement
State Sign-On Process Still To Play Out As Teva ‘Optimistic’ Of High Participation Rate
Teva has announced a finalized nationwide settlement over its long-running opioids litigation, signalling the start of a sign-on process for individual states, subdivisions and special districts. The company remains optimistic of a high participation rate.
You may also be interested in...
In just under six weeks Teva will have a new president and CEO, after former Sandoz chief Richard Francis was announced as Kåre Schultz’s replacement from the start of 2023.
Teva is on the hook to pay more than $300m to New York state over the next 18 years, in addition to $210m in damages already agreed under its proposed nationwide settlement deal, after settling claims with the New York Attorney General.
Shreehas Tambe has been named as CEO of Biocon Biologics, taking over from Arun Chandavarkar, in the wake of the company’s milestone $3bn transaction for Viatris’s biosimilars business.